A348150 Stock Overview
KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and neurological diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A348150 from our risk checks.
KoBioLabs, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩7,730.00 |
| 52 Week High | ₩14,150.00 |
| 52 Week Low | ₩6,990.00 |
| Beta | 0.80 |
| 1 Month Change | -3.25% |
| 3 Month Change | -17.77% |
| 1 Year Change | -40.58% |
| 3 Year Change | -79.36% |
| 5 Year Change | n/a |
| Change since IPO | -75.30% |
Recent News & Updates
Shareholder Returns
| A348150 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.5% | 4.2% | 0.8% |
| 1Y | -40.6% | 7.3% | 6.3% |
Return vs Industry: A348150 underperformed the KR Biotechs industry which returned 7.3% over the past year.
Return vs Market: A348150 underperformed the KR Market which returned 6.3% over the past year.
Price Volatility
| A348150 volatility | |
|---|---|
| A348150 Average Weekly Movement | 4.8% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.3% |
Stable Share Price: A348150's share price has been volatile over the past 3 months.
Volatility Over Time: A348150's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 48 | GwangPyo Ko | kobiolabs.com |
KoBioLabs, Inc. provides microbiome therapeutics for metabolic, immune, and neurological diseases. The company is based in Seongnam-si, South Korea.
KoBioLabs, Inc Fundamentals Summary
| A348150 fundamental statistics | |
|---|---|
| Market cap | ₩146.36b |
| Earnings (TTM) | -₩13.85b |
| Revenue (TTM) | ₩33.14b |
4.4x
P/S Ratio-10.6x
P/E RatioIs A348150 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A348150 income statement (TTM) | |
|---|---|
| Revenue | ₩33.14b |
| Cost of Revenue | ₩9.43b |
| Gross Profit | ₩23.71b |
| Other Expenses | ₩37.56b |
| Earnings | -₩13.85b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -731.63 |
| Gross Margin | 71.54% |
| Net Profit Margin | -41.80% |
| Debt/Equity Ratio | 28.9% |
How did A348150 perform over the long term?
See historical performance and comparison